Procaterol powder (72332-33-3)

October 25 [Fri], 2019, 20:47
Procaterol powder (72332-33-3)

Procaterol powder, a new beta‐2 adrenoceptor stimulant, was studied in a double‐blind, placebo‐controlled, cross‐over trial in patients with bronchial asthma. Oral procaterol 50μg b.d., procaterol 100 μg b.d., and terbutaline 5 mg t.i.d., were compared when given randomly in 1‐week treatment periods. The best clinical effect was found with terbutaline. Both anti‐asthmatic and tremorgenic effects of procaterol were dose‐related. Procaterol appeared effective in the doses tested, and a twice daily regimen would appear to be suitable with this drug.Procaterol powder

A procaterol-containing preparation for application to the skin which comprises a drug-retaining layer provided on a support, wherein said drug-retaining layer comprises a substantially water-free adhesive gel base comprising as essential components polyacrylic acid, a crosslinking agent and at least one lower alcohol or polyvalent alcohol, and 0.1 to 5% by weight of procaterol or a pharmaceutically acceptable salt thereof. Said preparation for application to the skin can be used as an external preparation for application to the skin which is capable of stably delivering procaterol or a salt thereof through the skin for a long time of period.

Procaterol powder is an intermediate-actingβ2 adrenoreceptor agonist used for the treatment of asthma. It has never been filed for FDA evaluation in the United States, where it is not marketed. The drug is readily oxidized in the presence of moisture and air, making it unsuitable for therapeuticuse by inhalation. Pharmaceutical company Parke-Davis/Warner-Lambert researched a stabilizer to prevent oxidation, but an effective one was never developed. It was patented in 1974 and came into medical use in 1980.
06 Procaterol (72332-33-3) Mechanism Of Action

Procaterol, A long-acting beta-2-adrenergic receptor agonist and a potentbronchodilator. Procaterol is only found in individuals that have used ortaken thisdrug that may be administered orally or by aerosol inhalation.Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
小文字 太字 斜体 下線 取り消し線 左寄せ 中央揃え 右寄せ テキストカラー 絵文字 プレビューON/OFF


「ヤプログ!利用規約 第9条 禁止事項」に該当するコメントは禁止します。